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Abstract
The ability to differentiate human pluripotent stem cells into endothelial cells with properties of 
cord-blood endothelial colony–forming cells (CB-ECFCs) may enable the derivation of clinically 
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relevant numbers of highly proliferative blood vessel–forming cells to restore endothelial function 
in patients with vascular disease. We describe a protocol to convert human induced pluripotent 
stem cells (hiPSCs) or embryonic stem cells (hESCs) into cells similar to CB-ECFCs at an 
efficiency of >108 ECFCs produced from each starting pluripotent stem cell. The CB-ECFC-like 
cells display a stable endothelial phenotype with high clonal proliferative potential and the 
capacity to form human vessels in mice and to repair the ischemic mouse retina and limb, and they 
lack teratoma formation potential. We identify Neuropilin-1 (NRP-1)-mediated activation of KDR 
signaling through VEGF165 as a critical mechanism for the emergence and maintenance of CB-
ECFC-like cells.
ECFCs, also called blood outgrowth endothelial cells1–3, are rare circulating endothelial 
cells, particularly abundant in umbilical cord blood, that display robust clonal proliferative 
potential and intrinsic in vivo blood vessel–forming ability4–7. ECFCs were shown to engraft 
in sex-mismatched human bone marrow transplant patients, with the most proliferative 
ECFCs displaying genetic markings of the donor marrow1. Although this study proved that 
ECFCs are directly transplantable without an intervening period of in vitro culture, it did not 
fully explain the cell of origin within the donor bone marrow that gives rise to ECFCs. 
ECFCs have shown promise for tissue regeneration. In mouse vascular injury models, they 
are rapidly recruited to the site of vascular injury or tissue ischemia after intravenous 
injection, where they initiate a vasculogenic response8, and they have been reported to 
enhance vascular repair and improve blood flow after myocardial infarction9, stroke3,10, 
ischemic retinopathy2 and ischemic limb injury8,11, and to engraft and re-endothelialize 
denuded vascular segments or implanted grafts12. In elderly patients and subjects with 
peripheral arterial disease (PAD) and critical limb ischemia, ECFCs may become prone to 
replicative senescence, reducing their reparative potential. To develop a source of CB-
ECFC-like cells for vascular repair, we investigated the use of human pluripotent stem cells 
(hPSCs)13,14 , which possess virtually unlimited self-renewal capacity and the ability to 
differentiate into any cell type in the body.
We began by studying whether previous protocols for generating endothelial cells from 
hPSCs generate cells with properties of CB-ECFCs, namely, high clonal proliferative 
potential with self-repopulating activity and robust in vivo vessel-forming ability4,6. Several 
of these protocols15–20 relied on co-culture with OP9 stromal cells16,20 or embryoid body 
formation15,18,19 followed by application of various growth factors and/or receptor signaling 
pathway inhibitors to promote endothelial cell differentiation. However, the derived 
endothelial cells are in some cases unstable, drifting to various nonendothelial phenotypes21, 
or exhibit low proliferative potential with a tendency to reach replicative senescence within 
5–7 passages18,19,21. We found that cells derived through co-culture with OP9 cells16 or 
through embryoid body formation15 do not have the specific characteristics of CB-ECFCs 
(Supplementary Figs. 1 and 2).
Next, we tested a more recent two-step endothelial-differentiation protocol that involves 
initial embryoid body formation and then two-dimensional (2D) adherent cell culture with 
added growth factors and a TGFβ inhibitor17 (Supplementary Fig. 3). Whereas this paper 
studied CD144+ cells, we undertook a more directed search for precursors of CB-ECFCs by 
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looking for other specific markers of endothelial cells in the cultures of differentiating cells. 
Undifferentiated human pluripotent stem cells express the endothelial marker VEGF 
receptor 2 (KDR) but not the endothelial markers NRP-1 and CD31. NRP-1 is expressed 
before CD31, CD34 and CD144 during endothelial line-age differentiation15 and has a well-
established role in cardiovascular development and angiogenesis22. Using the protocol of 
reference 17, we found that only NRP-1+CD31+ cells exhibited high clonal proliferative 
potential and in vivo vessel-forming ability in the continuous presence of TGFβ inhibition 
during both differentiation and maintenance (Supplementary Fig. 3). However, as shown 
previously17,21, endothelial cells derived by this protocol became unstable and lost high 
clonal proliferative potential and in vivo vessel-forming ability soon after TGFβ inhibition 
was removed (data not shown).
To develop a protocol for generating NRP-1+CD31+ cells with CB-ECFC properties that 
does not require embryoid body formation, co-culture with OP9 cells or TGF-β inhibition, 
we focused on generating different mesoderm subsets. Human pluripotent cells were 
cultured in 2D adherent cell culture with added growth factors in a serum-free culture 
condition (Fig. 1a). As Activin-A, BMP-4, FGF-2 and VEGF are critical for the emergence 
of mesoderm cells and the specification of endothelial cells from mesoderm cells17,23, we 
optimized the concentrations of these factors compared with previous protocols. A 
combination of these factors at a concentration of 10 ng/ml allowed us to enhance and 
isolate NRP-1+CD31+ cells capable of giving rise to stable CB-ECFC-like cells with clonal 
proliferative potential and in vivo vessel-forming capacity in the absence of TGFβ inhibition.
NRP-1+CD31+ cells gave rise to significantly more endothelial colonies than NRP-1−CD31+ 
cells (P < 0.001; Fig. 1b). NRP-1+CD31+ progeny were homogenous and displayed a 
cobblestone appearance (Fig. 1). A significant (15-fold) increase in total cell number was 
counted in 7-day expansion cultures initiated with NRP-1+CD31+ cells compared to 
NRP-1−CD31+ cells (P < 0.001; Fig. 1b). Further, cells grown from the NRP-1+CD31+ 
fraction exhibited surface co-expression of NRP-1 and CD31 (Fig. 1d) and uniform 
expression of CD144, but lacked expression of the mesenchymal marker α-SMA (Fig. 1d). 
Only 2% of the NRP-1+CD31+ cell subset failed to divide, and 48% formed high 
proliferative potential–ECFCs (HPP-ECFCs) (defined as single cell–derived colonies with 
>2,000 progeny that contain self-renewing clonal HPP-ECFC activity) (Fig. 1e and 
Supplementary Fig. 4e) with a colony cell number distribution very similar to that of CB-
ECFCs (Fig. 1e). Furthermore, NRP-1+CD31+ cells formed highly branching capillary 
structures (Fig. 1f). NRP-1+CD31+ cells produced endothelial cells with robust in vivo 
vessel-forming ability; the vessels inosculated with host mouse vessels (Fig. 1f,g), similar to 
CB-ECFCs previously described4,7. Notably, the NRP-1+CD31+ cells did not form 
teratomas after >6 months of implantation into immunodeficient mice (n = 24 animals; data 
not shown). Thus, hESC- and hiPSC-derived NRP-1+CD31+ cells displayed properties of 
ECFCs similar to CB-ECFCs and will be referred to hereafter as hESC-ECFCs or hiPSC-
ECFCs or, when discussing results derived from both, hPSC-ECFCs. hPSC-derived 
NRP-1−CD31+ cells did not show these properties (Supplementary Fig. 4).
We used two additional models to test the endothelial function of hiPSC-ECFCs, in addition 
to our subcutaneous implant method. We compared three study groups: (i) hiPSC-ECFCs, 
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(ii) hiPSC-embryoid body-derived TGFβ-inhibited CD144+ endothelial cells (hiPSC- EBT-
CD144+ ECs)17 and (iii) CB-ECFCs4,6. Although we sought to test a fourth study group, we 
were unable to derive enough hiPSC-embryoid body-derived KDR+NRP-1+ endothelial 
cells to perform these comparative studies.
In the first model, we measured rescue of blood vessel formation and reduction of 
neovascular tufts in newborn mice exposed to high oxygen concentration2. The oxygen-
induced retinopathy (OIR) in the neonatal pups results from hypoxia-induced loss of retinal 
vessels followed by an overexuberant retinal hypoxic response. A significant reduction of 
the post-injury avascular area occurred in retinas that received hiPSC-ECFCs (≥36% 
reduction; **P < 0.01) but not in retinas that received hiPSC-EBT-CD144+ ECs (≤14% 
reduction in avascular area; P = not significant (ns)) (Fig. 2a,b). In addition, only 
hiPSCECFCs significantly reduced preretinal neovascular tufts (Fig. 2c; hiPSC-EBT-
CD144+ EC results not shown). Prelabeling of the cells with Qdots 655 and imaging at 72 h 
after cell delivery showed that hiPSC-ECFCs integrated in higher numbers and with wider 
distribution in host retinal tissue compared with hiPSC-EBT-CD144+ ECs (Supplementary 
Fig. 5a). The hiPSC-ECFCs but not the hiPSC-EBTCD144+ ECs also appeared to form 
vascular tube structures in the superficial retinal plexus (Supplementary Fig. 5b).
We also studied a model of hind limb femoral vessel removal in nude mice24. Salvage of 
ischemic limbs and blood flow were significantly improved by hiPSC-ECFCs compared 
with hiPSC- EBT-CD144+ ECs (P < 0.05; Fig. 2d–f and data not shown). In these assays, 
hiPSC-ECFCs functioned similarly to CB-ECFCs.
Primary cells do not proliferate indefinitely but instead undergo senescence after long-term 
in vitro culture25. We could expand both hPSC-ECFCs and CB-ECFCs up to passage 18 
(P18) without loss of typical endothelial cell features (Supplementary Fig. 6a–c). Notably, 
although the majority of P18 hPSC-ECFCs and CB-ECFCs were senescent and exhibited 
characteristics of mortal primary cells25, they still maintained an endothelial cobblestone 
morphology and expression of endothelial antigens CD31, NRP-1 and CD144, but not α-
SMA (Supplementary Fig. 6d). Thus, hPSC-ECFCs maintained a stable endothelial 
phenotype throughout long-term expansion culture but, like any primary cell type, 
eventually exhibited replicative senescence.
To compare the various ECFC subsets at the transcriptional level, we performed whole-
transcriptome sequencing (RNA-seq) analysis on undifferentiated hiPSCs (hiPSC-day 0), 
day 3 differentiated hiPSCs (hiPSC-day 3), day 12 hiPSC-ECFCs, day 12 hESC-ECFCs and 
CB-ECFCs, as previously described21. Notably, both hiPSC- and hESC-ECFCs exhibited 
decreased expression of pluripotent and nonendothelial lineage–specific gene transcripts but 
increased expression of endothelial gene transcripts (Supplementary Fig. 7a,b), similar to 
CB-ECFCs.
We investigated an approach for enhancing the generation of hPSC-ECFCs. KDR has a 
well-established role in endothelial specification and maintenance, but it is unknown 
whether NRP-1 enhances KDR activation in hiPSCs undergoing ECFC lineage 
differentiation and increases the generation of stable ECFCs. It has been proposed that 
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NRP-1 on the endothelial cell surface binds to VEGF165 as a co-receptor with KDR22. 
Formation of NRP-1-VEGF165-KDR signaling complexes enhances VEGF-KDR-mediated 
signaling activity and biological function22,26,27. NRP-1 has also been clearly shown to be 
required for maximum KDR activity and/or KDR tyrosine phosphorylation22,26,27, and to 
selectively mediate VEGF-KDR signaling through p130Cas/Pyk2 activation in endothelial 
cells22. To study whether increasing NRP-1 activity would enhance KDR activation and the 
generation of hPSC-ECFCs, we screened for and identified the mesoderm subset with robust 
KDR expression and the first evidence of NRP-1 expression, which emerged on day 6 of 
hPSC differentiation (inset, Fig. 3b). We modulated NRP-1 expression in these cells with 
dimeric Fc-NRP-1, a surrogate for membrane NRP-1 (ref. 28), which enhances NRP-1 
activity, or the monoclonal antibody, NRP-1-B27, which blocks NRP-1 activity. Dose-
response experiments identified a specific dose (3.3 nM for Fc-NRP-1 dimer and 500 ng/ml 
for NRP-1-B) and length of time (4–6 d) for the treatment that gave reproducible results 
(data not shown and Fig. 3a) as reported27,28. After 4 d of treatment, Fc-NRP-1 dimer 
significantly increased (P < 0.01) and NRP-1-B significantly diminished (P < 0.001) 
generation of NRP-1+CD31+ cells (Fig. 3b). Fc-NRP-1 dimer treatment also increased 
activation of KDR and of p130Cas, a downstream molecule activated by NRP-1-mediated 
activation of KDR22 (Fig. 3c and Supplementary Fig. 8). In contrast, NRP-1-B–treated 
cells displayed decreased KDR phosphorylation and reduced activation of downstream 
molecules (Fig. 3c and Supplementary Fig. 8). These data suggest that NRP-1 enhanced 
the generation of ECFCs from human pluripotent stem cells by potentiating KDR signaling.
Next, we asked whether NRP-1 is also involved in the maintenance of the proliferative 
potential of cultured ECFCs. NRP-1 expression was progressively downregulated in late-
passage hPSC-ECFCs, and low levels of NRP-1 expression in late ECFCs were associated 
with decreased total proliferative potential (Fig. 4a,b). In late-passage (P14) hPSC-ECFCs, 
KDR was expressed in 50–60% of cells (Fig. 4c). However, when cultured in the presence 
of Fc-NRP-1 for 7 d, P14 hPSC-ECFCs displayed significantly increased (P < 0.001) 
expansion (Fig. 4d) but decreased β-galactosidase expression (senescence marker) compared 
to control and NRP-1-B–treated groups (Fig. 4e,f). Fc-NRP-1–treated P14 hPSC-ECFCs 
also displayed a significant decrease in the percentage of pro-apoptotic cells compared to 
control treated (P < 0.01) cells (Fig. 4g). Furthermore, the effects of Fc-NRP-1 on KDR 
activation were dependent upon the presence of VEGF165, as VEGF121 did not promote 
interaction between Fc-NRP-1 and KDR-positive P14 hPSC-ECFC (Fig. 4g–i). Thus, Fc-
NRP-1 activation of KDR by VEGF165 contributes to the rescue of proliferation and the 
reduction of expression of senescence markers and of pro-apoptotic behavior in near-
senescent hPSC-ECFCs.
Finally, preliminary studies showed that circulating and resident arterial-derived primary 
endothelial cells derived from patients with PAD and critical limb ischemia exhibited low 
levels of NRP-1 expression, possessed low clonal proliferative potential, exhibited markers 
of senescence and did not form robust in vivo human vessels upon implantation in 
immunodeficient mice (Supplementary Fig. 9a–g). However, Fc-NRP-1 treatment 
facilitated proliferation, survival and modestly diminished evidence of senescence in these 
cells (Supplementary Fig. 9h–n). Thus, Fc-NRP-1 treatment of late-passage, near-
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senescent hiPSC-ECFCs and patient-derived PAD-ECs increases proliferative potential, 
decreases apoptosis and diminishes markers of senescence in a VEGF165-dependent fashion.
In this study we have established a method to reproducibly derive and isolate a homogenous 
and stable population of pluripotent stem cell–derived endothelial cells possessing CB-
ECFC properties: formation of a homogenous monolayer with characteristic cobblestone 
appearance, high clonal proliferative potential, formation of capillary structures when 
cultured on Matrigel and generation of robust in vivo-inosculated vessels after implantation 
in immune-deficient mice. By assaying for specific CB-ECFC properties rather than simply 
relying on classical cell surface expression of ‘endothelial’ markers or gene expression 
patterns, we derived ECFCs that we did not detect among the endothelial cells derived by 
previous methods15–17. The hiPSC-ECFCs significantly contributed to vascular repair of 
experimentally induced ischemic limbs and hyperoxic injured retinas in murine models, 
similar to CB-ECFCs, and were superior to endothelial cells isolated using other published 
protocols15–17. They were stable and did not transition to nonendothelial cells over 
prolonged culture (18 passages) and could expand to over a trillion endothelial cells in less 
than 3 months (Fig. 1a). This efficient output of functional endothelial cells contrasts with 
previous reported yields of 0.6 (ref. 16), 7.4 (ref. 17) and 11.6 (ref. 29) endothelial cells 
from differentiated human pluripotent stem cells. We also found that NRP-1-VEGF165-
KDR–mediated activation of KDR is a critical mechanism both for derivation of hPSC-
ECFCs and for enhancing survival and proliferative potential of late-passage, near- 
senescent hPSC-ECFCs and patient-derived ECFCs. Our results may enable highly efficient 
production of patient-derived ECFCs for the treatment of cardiovascular disease.
ONLINE METHODS
Culturing of hESCs and hiPSC
hESC line H9 (ref. 13) and fibroblast-derived human iPSC line (DF19-9-11T)14 were 
purchased from WiCell Research institute (Madison, Wisconsin). Several other hiPSC lines 
(FCB-iPS-1 and FCB-iPS-2) derived in the Broxmeyer and Yoder laboratories were also 
used to generate ECFCs30,31 (Supplementary Table 1). Both hESCs and hiPSCs were 
maintained in mTeSR1 complete media (Stem Cell Technologies) on Matrigel in 10 cm2 
tissue culture dishes at 37 °C and 5% CO2. After the plating of cells, media was changed on 
days 2, 3 and 4. Cells were passaged on day 5. Media was aspirated and 4–5 ml of dispase (2 
mg/ml, Gibco) containing media was added to the plate and incubated at 37 °C for 3–5 min 
or until the edges of the colonies had lifted from the plate. Dispase containing media was 
aspirated from the plate and cells were gently washed with DMEM-F12 (Gibco) three times 
to remove any residual amount of enzyme. Fresh media was then used to collect colonies 
from the plate using a forceful wash and scraping with a 5-ml disposable pipette taking care 
to avoid bubbles. Collected colonies were then centrifuged at 300 g for 5 min. The 
supernatant was aspirated and pellet was resuspended in mTeSR1 complete media. Prior to 
passaging, 10 cm2 tissue culture dishes were coated with Matrigel for 30 min. Unattached 
Matrigel was removed from the tissue culture dishes and 7 ml of mTeSR1 complete medium 
was added to dishes. Colonies evenly distributed in mTeSR1 media were added to each 
plate. Cells were then spread out within the dish using multiple side-to-side shaking motions 
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while avoiding any swirling. Cultures were checked for growth quality and morphology, and 
by performing teratoma formation assay as previously described31.
Directed differentiation of hESCs and hiPSCs into the ECFC lineage
After 2 d (-D2) of culture in mTeSR1 media, cultures were directed toward the mesodermal 
lineage with addition of activin A (10 ng/ml) in the presence of FGF-2, VEGF165 and BMP4 
(10 ng/ml) for 24 h. The following day, activin-A containing media was removed and 
replaced with 8 ml of Stemline II complete media (Sigma) containing FGF-2 (Stemgent), 
VEGF165 (R&D) and BMP4 (R&D) to promote endothelial cell emergence and expansion. 
Media was replaced with 8 ml of fresh Stemline II differentiation media on days 3, 5, 7 and 
8. On day 9 and thereafter media was changed with 10 ml of Stemline II differentiation 
media.
Flow cytometry
At day 12 after differentiation, adherent cells were harvested using TrypleE and made into a 
single-cell suspension in EGM-2 medium. Cells were counted and aliquots of the cell 
suspension were prepared for antibody staining. FcR blocking reagent (Miltenyi Biotech) 
was added to prevent the non-specific binding of antibodies. Anti-human CD31 (CD31-
FITC, clone WM59 from BD Pharmingen), CD144 (CD144-PE, clone 16B1 from 
eBioscience) and NRP-1 (NRP-1-APC, clone AD5-176 from Miltenyi Biotech) antibodies 
were used at concentrations that were titrated before use (Supplementary Table 2). 
Propidium iodide (PI, Sigma) was added to the cell suspension for dead cell staining. Flow 
cytometric detection of the cell surface antigens and cells sorting were performed on an LSR 
II and FACSAria (Becton Dickinson), respectively. Compensation was set by single-positive 
controls using cord blood–derived ECFCs. A gating of targeted cell population was 
determined based on fluorescent minus one (FMO) controls for each fluorescent color.
Cell culture of sorted cells
CD31+-, CD144+- or KDR+- and NRP-1+–sorted cells were centrifuged at 300 g for 5 min 
then resuspended in 50% EGM-2 and 50% complete Stemline II differentiation media. To 
generate ECFCs from the sorted population, 2,500 cells per well were seeded on rat tail type 
I collagen-coated 12-well plates. After 2 d, the media was aspirated and three parts of 
EGM-2 and one part of differentiation media was added to the cultures. ECFC colonies 
appeared as tightly adherent cells and exhibited cobblestone morphology on day 7. On 
occasion, cloning cylinders were used to isolate ECFC colonies from heterogeneous cell 
populations. Cloning of endothelial cell clusters was performed to isolate pure populations 
of highly proliferative endothelial cells as described previously4,5. Confluent ECFCs were 
passaged by plating 10,000 cells per cm2 as a seeding density and ECFCs were maintained 
in complete endothelial growth media (collagen coated plates and cEGM-2 media) with 
media change every other day as described previously4,5.
In vitro capillary network formation assay on Matrigel
Endothelial cells derived from different protocols were trypsinized and resuspended in 
EGM-2 media. Cells were plated at a density of 1.0 × 104 cells per well in triplicate in 96-
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well plates coated with 50 μl of growth factor–reduced Matrigel (BD Biosciences). Plates 
were incubated overnight at 37 °C. After 8–16 h of incubation, photomicrographs were 
taken from each well at 10× magnification using a Zeiss Axiovert 25 CFL inverted 
microscope with a 10× CP-ACHROMAT/0.12 NA objective. Images were acquired using a 
SPOT RT color camera (Diagnostic Instruments) with the manufacturer's software. Phase 
contrast images were taken with air objectives.
Immunochemistry
ECFCs were fixed with 4% (w/v) paraformaldehyde for 30 min and permeabilized with 
0.1% (v/v) Triton X-100 in PBS for 5 min. After blocking with 10% (v/v) goat serum for 30 
min, cells were incubated with primary following antibodies; anti-CD31 (Santa Cruz), anti-
CD144 (Ebioscience), anti-NRP-1 (Santa Cruz) and anti-a-SMA, (Chemicon) overnight at 4 
°C. Cells were washed with PBS, then incubated with secondary antibodies conjugated with 
Alexa-488 or Alexa-565 (Molecular Probe) and visualized by confocal microscopy after 
counterstaining with 2 g/ml DAPI (Sigma-Aldrich). The confocal images were obtained 
with an Olympus FV1000 mpE confocal microscope using as an Olympus uplanSApo 
60xW/1.2NA/eus objective. All the images were taken as Z-stacks with individual 10-μm 
thick sections at room temperature and images were analyzed using FV10-ASW 3.0 Viewer.
Single-cell assay
CB-ECFCs or iPSC-ECFCs or hESC-ECFCs or hiPSCEBT-CD144+ ECs and PAD-derived 
ECs were subjected to a single-cell assay to evaluate clonogenic proliferative potential. 
Briefly, endothelial cells were treated with trypLE Express (Invitrogen) to obtain a single-
cell suspension. Cell counts and serial dilutions were performed to obtain a concentration of 
0.68 cells per well in individual wells of 96-well culture plates. Wells were examined the 
day after plating to ensure the presence of a single cell per well. Culture media was changed 
on days 4, 8 and 12. On day 14 of culture, cells were stained with Sytox reagent 
(Invitrogen), and each well was examined to quantitate the number of cells using a 
fluorescent microscope. Those wells containing two or more cells were identified as positive 
for proliferation under a fluorescent microscope at 10× magnification using a Zeiss Axiovert 
25 CFL inverted microscope with a 10 × CP-ACHROMAT/0.12 NA objective. Wells with 
endothelial cell counts of 2–50, 51–500, 501–2,000 and ≥2,001 were labeled as endothelial 
cell clusters (ECCs), low proliferative potential ECFCs (LPP) and high proliferative 
potential ECFCs (HPP), as previously described4,5.
Cell viability, senescence and cell proliferation assay
Endothelial cells were plated at a density of 5 × 104 per well or 1 × 105 per well on type I 
collagen–coated 12-well and 6-well plates, respectively. After 24 h, growth media was 
replaced with Fc-control, Fc-NRP-1 dimer (R&D Systems) or NRP-1 blocking antibodies 
containing EGM-2 medium for 7 d and media was replaced on every alternative day. 
NRP-1A and NRP-1B antibodies were generously provided by Genentech27. Cell viability 
and proliferation was assessed by Trypan blue exclusion, and the numbers of dye-free cells 
were counted under a phase microscope in triplicate per condition.
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A senescence assay kit was purchased from Biovision, and the assay performed according to 
the manufacturer's instructions. Briefly, endothelial cells were seeded onto 12-well plates for 
overnight culture to form a monolayer. The following day, cells were fixed in 0.5 ml of the 
commercial fixative solution for 10–15 min at room temperature. Cells were washed twice 
with 1 ml of 1× PBS and stained with 0.5 ml of the commercial staining solution for 
overnight at 37 °C. Cells were observed under a microscope for development of a blue color. 
Photomicrographs were taken from each well at 10× magnification using a Zeiss Axiovert 
25 CFL inverted microscope with a 10× CP-ACHROMAT/0.12 NA objective. Images were 
acquired using a SPOT RT color camera (Diagnostic Instruments) with the manufacturer's 
software. Phase contrast images were taken with air objectives.
Mice
All animal procedures were carried in accordance with the Guidelines for the Care and Use 
of Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committees (IACUCs) at Indiana University School of Medicine (IACUC protocol # 
10170). Both male and female 6- to 12-week-old nonobese/severe combined 
immunodeficient (NOD/SCID) mice (T- and B-cell deficient, impaired complement) were 
used for all animal studies. NODSCID mice were maintained under specific-pathogen-free 
conditions at the Indiana University Laboratory Animal Resource Center (LARC). Previous 
work with this animal model was used to determine the minimum number of animals needed 
to obtain statistically significant results4. Previous studies have shown that 8 out of 10 
matrices (one animal received two matrices) implanted inosculate with the host vasculature 
and that 8 matrices (4 animals) with functional vessels are needed for each group for 
statistical significance4. Method of randomization was not used while allocating samples 
and animals to each experimental group. Also, investigator was not blinded to the group 
allocation either during the experiment or when accessing the outcomes.
In vivo vessel formation assay
Pig skin type I collagen was used to generate three-dimensional (3D) cellularized collagen 
matrices as previously described7. Briefly, type 1 collagen gel mixture was prepared by 
mixing together ice-cold porcine skin collagen solution in 0.01N HCL, and neutralized with 
phosphate buffered saline and 0.1N NaOH to achieve neutral pH (7.4). Neutralized gel 
mixtures (~1.5 mg/ml) were kept on ice before induction of polymerization by warming at 
37 °C, in 5% CO2. Cultured ECFCs were added to the collagen mixture to a final 
concentration of two million cells/ml collagen. The collagen mixture (250 μl) containing the 
ECFCs suspension was added to 48-well tissue culture dishes and was allowed to 
polymerize to form gels by incubation in a CO2 incubator at 37 °C for 30 min. The gels 
were then overlaid with 500 μl of culture medium for overnight at 37 °C, in 5% CO2.
After 18 h of ex vivo culture, cellularized gels were implanted into the flanks (a bluntly 
dissected subcutaneous pouch of anterior abdominal wall with close proximity of host 
vasculature) of 6- to 12-week-old NOD/SCID mice, as previously described4. Surgical 
procedures to implant collagen gels were conducted under anesthesia and constant supply of 
oxygen. Incisions were sutured and mice monitored for recovery. Two weeks after 
implantation, gels were recovered by excising engrafts in animals that had been humanely 
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euthanized per approved IACUC protocol. Immunohistochemistry was performed as 
described previously using H&E and anti-human CD31 staining to examine the gels for 
human endothelial-lined vessels perfused with mouse red blood cells. hCD31+ blood vessels 
were imaged from each explant using a Leica DM 4000B microscope (Leica Microsystems) 
with attached Spot-KE digital camera (Diagnostic Instruments). Functional vessels were 
counted only if they contained at least 1 mouse erythrocyte.
Oxygen-induced retinopathy model
All experiments were performed in conformity to the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research and the UK Home Office Regulations. 
Oxygen-induced retinopathy was induced in C57/BL6 wild-type mice, as previously 
described2. Briefly, postnatal day (P) 7 newborn mice and their nursing dams were exposed 
to 75% oxygen (Pro-Ox 110 Chamber Controller; Biospherix, Redfield, NY) for 5 d. At P12 
they were transferred back to room air. At P13, mice received a 1 μl intravitreal injection 
containing 1 × 105 hiPSC-ECFCs, hiPSC-EBT-CD144+ ECs or CB-ECFCs that had 
previously been labeled (Qtracker 655; Invitrogen). Phenol red–free DMEM without growth 
factors and serum was used as vehicle and injected in the left eye of each pup as a control. 
All pups were euthanized 72 h later with sodium pentobarbital and eyes fixed in 4% 
paraformaldehyde. Retinal flat mounts were stained with isolectin B4 (Sigma) and 
streptavidin-AlexaFlour488 (Invitrogen), and stained retinas were visualized and imaged 
using a confocal microscope. Area quantification was performed using ImageJ software by 
three independent, blinded investigators as described2.
Mouse hind limb ischemia model
Hind limb ischemia experiments were performed as we previously described24. Briefly, 6-
week-old male athymic nude mice (body weight 25–30 g; Orient bioAnimal Inc., Seoul, 
Korea) were anesthetized with rompun (20 mg/kg) and ketamine (100 mg/kg). The femoral 
artery and its branches were ligated through a skin incision with 6-0 silk (Ethicon). The 
external iliac artery and all of the arteries above it were then ligated. The femoral artery was 
excised from its proximal origin as a branch of the external iliac artery to the distal point 
where it bifurcates into the saphenous and popliteal arteries. Immediately after arterial 
dissection, athymic mice were randomly assigned to 1 of 4 experimental groups. After the 
ischemic surgery, the hiPSC-ECFCs or CB-ECFCs or hiPS-EBT-CD144+ ECs (1.0 × 106 
cells per mouse) were suspended in 200 μl of EGM-2 and these cells or vehicle control were 
injected intramuscularly into six sites of the gracilis muscle in the medial thigh with 29-
gauge tuberculin syringes. A Laser Doppler perfusion imager (Moor Instruments) was used 
to measure the blood flow in the hind limbs on days 0 and 28 post-treatment as previously 
described24. Digital color-coded images were analyzed to quantify the blood flow in the 
region from the knee joint to the toe, and the mean perfusion values were calculated. All 
animal care and experimental procedures for hind limb ischemia experiments were 
performed under the approval of the animal care committees of CHA University (IACUC 
No. 130024).
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Isolation of arterial ECFCs from patients with peripheral vascular disease (PAD)
De-identified patient materials (Disease artery (DA) ECFCs) were obtained from patients 
with peripheral vascular disease who underwent lower extremity amputations following 
informed consent and use of a protocol that was approved by the Indiana University and the 
Richard L. Roudebush VA Medical Center human IRB panel (IRB # 1011004004). Patients 
with active cellulitis, purulent drainage or wet gangrene were not used in this study, due to 
the high risk of yeast contamination. Likewise, patients with hepatitis B or C, and patients 
with HIV were excluded from this study. Following transection, amputated legs were 
immediately explored in the operating room for suitable specimens of arteries on a sterile 
table separate from the operative field. Samples deemed suitable were placed into a 
container filled with Hank's balanced salt solution (HBSS; Invitrogen) and taken to the 
laboratory for processing. Under sterile conditions, the vessels were opened lengthwise in a 
tissue culture dish and immersed in EGM-2 culture media (Lonza). The intima of each 
vessel was scraped with a cell scraper (TPP) and washed with DMEM. The cell fraction left 
from the washings was centrifuged at 1620 r.p.m. for 10 min, after which it was plated onto 
rat-tail type I collagen coated six-well plates. After several days, growing endothelial 
colonies could be seen by light microscopy, and these colonies were isolated with cloning 
cylinders, trypsinized and replated onto new six-well plates to prevent mesenchymal cell 
contamination. The purified ECFCs were passaged 1 to 2 times more, and then expanded in 
T-75 tissue culture flasks (TPP) before cryopreservation.
Culture of endothelial cells from peripheral blood of PAD patient
Mononuclear cells isolated from each patient peripheral blood or cord blood were seeded on 
6-well tissue culture plate precoated with type I rat tail collagen and were cultured in 
complete endothelial growth medium (EGM-2) supplemented with 10% FBS, 2% penicillin-
streptomycin. Cells were maintained in a 37 °C, 5% CO2 humidified incubator, and medium 
was changed every other day for 2–3 weeks or until cobblestone-appearing endothelial 
colonies appeared. After initial appearance of colonies, cells were transferred to a new well 
of a 6-well plate and further passaged in 25-cm2 flasks and at passages at 85–95% 
confluence. PAD cells at passages 3–7 at approximately 70% confluence were used in all 
studies.
Western blot analysis
Cell lysates were prepared by resuspending cells in lysis buffer (20 mM Tris-HCl pH 7.5, 
150 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 1 mM Na3VO4, 1 μg/ml each 
of aprotinin and leupeptin) followed by incubation on ice for 20 min. Insoluble components 
were removed by centrifugation at 12,000g for 15 min. Protein concentrations were 
determined with a protein assay kit (Bio-Rad). Proteins were separated by electrophoresis on 
4–20%Tris-glycine minigels and then transferred onto immobilon-FL PVDF membrane 
(Millipore). Nonspecific binding was blocked with blocking buffer for 1 h at room 
temperature and incubated overnight at 4 °C with primary antibodies against phospho-PYK2 
(1:1,000; Cell Signaling) and phospho-p130Cas (1:1,000; Cell Signaling) in Odyssey 
blocking buffer. Blots were washed with PBS containing 0.1% Tween20, followed by 
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incubation for 1 h at room temperature with anti-rabbit antibody (1:10,000; LI-COR). 
Immunoreactive bands were detected using the Odyssey Infrared Imager (LI-COR).
RNA sequence library construction, sequencing and analysis
Total RNA was isolated from the samples using Trizol reagent (Invitrogen) and the RNA 
quality was examined as previously described21. RNA sequence library was generated using 
1 μg of high-quality total RNA and sequencing was performed using Illumina HiSeq2000 
sequencer as previously described21. The resulting sequence reads were mapped to the 
human genome (hg18) using TopHat with default parameters, and the RefSeq (June 2010) 
transcript levels (FPKMs) were quantified using CuffLinks. Heatmaps of select transcripts 
were then plotted using red-to-green scale using R statistical software package of heatmap.2 
from RNA-seq data.
Statistical analysis
All experiments were performed ≥3 times in triplicate and data are represented as mean 
value ± s.d. for statistical comparison. A power of analysis with a 95% confidence interval 
was used to calculate sample size required to obtain statistically significant results. The 
sampling number we used gave a normal distribution. Significance of differences was 
assessed by a two-tailed Student's t-test or one way ANOVA-Tukey post-hoc test Multiple 
Comparison Test or chi-squared test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Simple one-step, 2D, serum-free, endothelial lineage differentiation protocol does not 
require embryoid body formation or TGF-β inhibition and yields ECFCs similar to those 
found in cord blood. (a) Schematic representation showing an estimation of generation of 
over a trillion cells in 61 d, starting from 104 hESCs or hiPSCs. Generation of 3 × 104 
NRP-1+CD31+ cells in 12 d is shown on left. A representative flow cytometry contour plot 
(bottom right) indicates the percent expression of NRP-1 and CD31 in day 12 differentiated 
cells. Day 12 NRP-1+CD31+ cells give rise to stable ECFC colonies that undergo extensive 
expansion. (b) Day 12 differentiated cells were sorted for NRP-1+CD31+ and 
NRP-1−CD31+ cell fractions and cultured in transitioning media for endothelial growth. 
NRP-1+CD31+ cells gave rise to 60% more endothelial colonies (left panel) and 15-fold 
more total endothelial cells (right panel) compared to NRP-1−CD31+ cells in 7 d of culture. 
n = 5; mean ± s.d. Student's t-test: ***P < 0.001. (c) A representative photomicrograph of 
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ECFC colony obtained from NRP-1+CD31+ cell fraction exhibiting characteristic 
cobblestone morphology containing homogenous population of endothelial cells within each 
colony. Experiments were performed eight times in duplicate. Scale bars, 50 μm. (d) 
Representative immunofluorescence micrographs of ECFCs exhibiting cell surface 
expression for typical endothelial markers CD31, CD144 and NRP-1 and the nonendothelial 
marker α-SMA. Left, NRP-1 expression (red); CD31 (green). Right, α-SMA (green); 
CD144 (red). Nucleus (DAPI, blue). All experiments were performed three times in 
duplicate. Scale bars, 50 μm. (e) Clonal proliferative analysis of hESC-ECFCs and hiPSC-
ECFCs in comparison with CB-ECFC control. The distribution pattern of colonies formed 
by clones of hESC-ECFCs and hiPSC-ECFCs formed HPPs (≥2,001 cells/well) and low PPs 
(51–2,000 cells/well) similar to levels produced by CB-ECFCs. n = 3; mean ± s.d. Student's 
t-test: P value not significant (ns). (f) Representative phase-contrast photomicrographs of 
hiPSC-ECFCs’ characteristic cobblestone morphology and formation of complete capillary 
networks on Matrigel similar to that exhibited by CB-ECFCs. All experiments were 
performed five times in duplicate. Scale bars, 100 μm. (g) ECFCs form durable and 
functional in vivo human vessels in immunodeficient mice. ECFCs (both from cord blood 
and hiPSCs) containing cellularized collagen gels were implanted in immunodeficient 
(NOD/SCID) mice in a subcutaneous pouch, recovered 14 d later, and fixed and stained. 
Arrows in the representative photomicrograph depict anti-human CD31+-stained functional 
human blood vessels that are perfused with circulating host mouse red blood cells. Scale bar, 
50 μm. A bar graph represents quantification of functional hCD31+ vessels counted per mm2 
in each group. n = 3; mean ± s.d. Student's t-test: ns.
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Figure 2. 
Human iPSC-ECFCs contribute to vascular repair of both ischemic retina and limb. (a) 
Representative flat-mounted retinas of C57/BL6 mice injected with vehicle (left) or hiPSC-
ECFCs (right). Retinal vasculature stained in green with Isolectin B4. Avascular area 
indicated by white line. All experiments were performed ≥4 times and percentage of 
avascular area calculated. Scale bars, 1 mm. (b) Representative flat-mounted retinas of 
C57/BL6 mice injected with vehicle (left) or hiPSC-EBT-CD144+ ECs (right). Retinal 
vasculature stained in green with Isolectin B4. Avascular area indicated by white line. All 
experiments were performed ≥4 times and percentage of avascular area calculated. Scale 
bars, 1 mm. (c) Representative pathological preretinal neovascularisation in C57/BL6 mice 
injected with vehicle (left) or hiPSC-ECFCs (right). Preretinal neovascular tufts 
predominately seen in vehicle-injected eyes when compared to contra lateral hiPSC-ECFCs–
injected eyes. Arrows indicate preretinal neovascular tufts. All experiments were performed 
≥4 times. Scale bars, 200 μm. (d) Representative laser Doppler perfusion imaging showing 
therapeutic neovascularization by hiPSC-ECFCs in athymic nude mice. A greater increase in 
limb blood perfusion was observed in the ischemic limbs (arrow) of mice that received 
hiPSC-ECFCs or CB-ECFCs transplantation than in the vehicle or hiPSC-EBT-CD144+ 
ECs-injection groups. All experiments were performed ≥10 times. (e) A stacked bar graph 
represents the percentage distribution of the physiological status of the instrumented 
ischemic limbs on day 28 post-implantation of vehicle, hiPSC-ECFCs, hiPSC-EBT-CD144+ 
ECs or CB-ECFCs. All experiments were performed ≥10 times. (f) A table represents the 
physiological status of the ischemic limbs on day 28 post-implantation of vehicle, hiPSC-
ECFCs, hiPSC-EBT-CD144+ ECs or CB-ECFCs. All experiments were performed ≥10 
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times and values represent percentage limb salvage, necrosis or loss. Parametric Chi-squared 
test: *P < 0.05.
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Figure 3. 
NRP-1 is critical for the emergence of ECFCs from hPSCs. (a) Schematic representation of 
the treatment strategy in examining the role of NRP-1 in the emergence of ECFCs from 
hPSCs. (b) Quantification of the percentage emergence of NRP-1+CD31+ (double)- positive 
cells following treatments with control (blue), Fc-NRP-1 (brown) and NRP-1-B (green) on 
days 10 and 12 of differentiation. A significantly increased percent emergence of double-
positive cells was observed in the Fc-NRP-1–treated group compared to the control group. 
However, generation of double-positive cells was significantly lower in the NRP-1-B–
treated group compared to the control. In the inset, a flow cytometry contour plot indicates 
the percent expression of KDR and NRP-1 in day 6 differentiated cells showing abundant 
KDR expression and diminished NRP-1 expression. n = 3; mean ± s.d. Student's t-test: **P 
< 0.01 and ***P < 0.001. (c) Western blots showing KDR, p130Cas and Pyk2 
phosphorylation. Top, hPSCs undergoing ECFC differentiation were treated with Fc-control, 
Fc-NRP-1 dimer or NRP-1-B as described in a, starved, then stimulated with VEGF165. Cell 
lysates were treated with antibodies against phospho-KDR and total KDR. The expression of 
phosphor-KDR in NRP-1 dimer– and NRP-1-B–treated hiPSCs is shown in top blot and 
total KDR levels for each lane is depicted in the bottom blot. KDR phosphorylation was 
observed in VEGF-stimulated groups, and Fc-NRP-1 dimer treatment increased 
phosphorylation of KDR compared to control-treated cells. However, lower phosphorylation 
was observed in NRP-1-B–treated cells. Average band intensity value was normalized to 
total protein for each of the bands, and the normalized band intensity for each group 
compared with the VEGF-untreated group. In the bottom panels, hiPSCs undergoing ECFC 
differentiation were treated with the indicated concentration of Fc-control (C), Fc-NRP-1 
dimer or NRP-1-B, starved, then stimulated with VEGF165. Cell lysates were treated with 
antibodies against phospho-p130Cas, phospho-Pyk2 and total Pyk2 and run on a western 
blot. Increased P-130Cas and Pyk2 phosphorylation was observed in a dose-dependent 
manner in the Fc-NRP-1 dimer–treated group compared to control-treated cells. However, 
lower P-130Cas and Pyk2 phosphorylation was observed in NRP-1-B–treated cells compared 
to control-treated cells. Average band intensity value was normalized to total protein for 
each of the bands and the normalized band intensity for each group compared with the band 
intensity for the control. All experiments were performed three times and representative 
cropped photomicrographs are shown with quantification of the band intensity at the bottom 
of each blot. Full-length blots are presented in Supplementary Figure 9.
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Figure 4. 
NRP-1 is critical for the maintenance of ECFC proliferative potential. (a) Human PSC-
ECFCs from different passages (P4, P14 and P18) were stained with monoclonal antibodies 
against CD31, CD144 and NRP-1. Percentages in each contour plot indicates CD31 and 
CD144 double-positive cells (left panel), whereas percentages in the right panel contour plot 
indicates CD31 and NRP-1 double-positive cells. The percentage of CD31/CD144 double-
positive cells was maintained at higher levels in all of these different passages, whereas the 
percentage of NRP-1/CD31 double-positive cells progressively decreased in late passages. 
All experiments were performed four times in duplicate and a representative contour plot is 
shown for each group. (b) Fold expansion of hPSC-ECFCs when cells were counted at 
different passages (P4, P14 and P18) after 7 d of culture. Progressive loss in fold-expansion 
ability was observed in late-passage cells. n = 4; mean ± s.d. Student's t-test: ***P < 0.001. 
(c) P14 hPSC-ECFCs were stained with monoclonal antibodies against KDR and NRP-1. 
Percentages in each contour plot indicate NRP-1– and KDR-positive cells. Although more 
than 50% of the cells exhibited KDR expression, fewer than 17% cells exhibited NRP-1 
expression. All experiments were performed four times in duplicate and a representative 
contour plot is shown. (d) Late passage (P14) hPSC-ECFCs were treated with control, Fc-
NRP-1 and NRP-1-B to examine fold expansion after 3 or 7 d of treatment. A bar graph 
represents fold expansion of late passage (P14) hPSC-ECFCs following 3 (left bar graph) 
and 7 d (right bar graph) of treatment with control, Fc-NRP-1 and NRP-1-B. A significantly 
increased fold expansion was observed in Fc-NRP-1–treated cells both at day 3 and day 7 
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compared to control. However, a significantly decreased cell expansion was observed in the 
NRP-1-B–treated group both at day 3 and day 7 compared to control. n ≥ 3; mean ± s.d. 
Student's t-test: *P < 0.05, **P < 0.01 and ***P < 0.001. (e) Late passage (P14) hPSC-
ECFCs were treated with control, Fc-NRP-1 and NRP-1-B for 7 d and were stained with β-
galactosidase as per manufacturer's instruction. Fc-NRP-1 treatment decreased the number 
of β-galactosidase–positive blue cells (dotted circles) compared to control-treated cells. 
Whereas, NRP-1-B treatment increased the number of blue cells compared to control. All 
experiments were performed 4 times in triplicate and a representative photomicrograph is 
shown for each group. Scale bar, 50 μm. (f) Percentages of β-galactosidase–positive blue 
cells following the treatment of late passage (14) hPSC-ECFCs with control, Fc-NRP-1 and 
NRP-1-B for 7 d. A significantly decreased percentage of blue cells were observed in the 
Fc-NRP-1–treated group compared to control group. However, a significantly increased 
percentage of blue cells were observed in the NRP-1-B–treated group compared to control. n 
= 6; mean ± s.d. Student's t-test: **P < 0.01 and ***P < 0.001. (g) Late passage (p14) 
hPSC-ECFCs were cultured in regular EGM-2 media containing VEGF165 and EGM-2 
media with VEGF121 and these cells were treated with control, Fc-NRP-1 and NRP-1-B for 
7 d. After 7 d cells were collected, counted and stained with propidium iodide and annexin 
V to examine for live, proapoptotic, and dead cells in each of these treatment groups. A bar 
graph represents the percentage of proapoptotic cells in VEGF165 and VEGF121 containing 
media following 7 d of treatment with control, Fc-NRP-1 and NRP-1-B. A significantly 
decreased percentage of pro-apoptotic cells were observed in both Fc-NRP-1 and NRP-1-B 
treated groups in cells cultured in VEGF165 containing media compared to cells cultured in 
the presence of VEGF121. n ≥ 3; mean ± s.d. Student's t-test: **P < 0.01. (h) Late passage 
(P14) hPSC-ECFCs were cultured in EGM-2 media where regular VEGF165 was replaced 
with VEGF121 and these cells were treated with control, Fc-NRP-1 and NRP-1-B for 7 d. A 
bar graph represents fold expansion of late passage (14) hiPSC-ECFCs in VEGF121 treated 
media following 7 d of treatment with control, Fc-NRP-1 and NRP-1-B. Fc-NRP-1 and 
NRP-1-B treatment did not cause significant alteration in fold expansion in these cells 
compared to control in the presence of VEGF121. n = 4; mean ± s.d. Student's t-test; ns. (i) 
Late passage (p14) hPSC-ECFCs were cultured in regular EGM-2 media containing 
VEGF165 and EGM-2 media with VEGF121 and these cells were treated with control, Fc-
NRP-1 and NRP-1-B for 7 d. After 7 d, cells were collected, counted and stained with 
propidium iodide and annexin V to examine for live, proapoptotic and dead cells in each of 
these treatment groups. Percentages in each contour plots represent live, proapoptotic and 
dead cells in control (left panels), Fc-NRP-1– (middle panels) and NRP-1-B– (right panels) 
treated cells in the presence of VEGF121 (panels on top row) or VEGF165 (panels on bottom 
row). In the VEGF121-treated cells, both Fc-NRP-1 and NRP-1-B increased the percentage 
of dead and pro-apoptotic cells compared to control. However, in VEGF165-treated cells, 
while Fc-NRP-1 decreased the percentages of both dead and proapoptotic cells and 
increased the percentage of live cells compared to control, NRP-1-B increased the 
percentages of both dead and proapoptotic cells and decreased the percentage of live cells 
compared to control. All experiments were performed four times in triplicate and a 
representative contour plot is shown for each group.
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